Analgesics
Antiandrogens
Antihistamines
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Monoclonals
Mpro inhibitors
Naso/orophar..
Nigella Sativa
Nitazoxanide
PPIs
Quercetin
RdRp inhibitors
Thermotherapy
Vitamins
More

Other
Feedback
Home
 
next
study
previous
study
c19early.org COVID-19 treatment researchTixagevimab/cilgavimabTixagev../c.. (more..)
Metformin Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta
Ivermectin Meta Thermotherapy Meta
Melatonin Meta

All Studies   Meta Analysis       

Effective Treatment of COVID-19 Infection with Repurposed Drugs: Case Reports

Enyeji et al., Viral Immunology, doi:10.1089/vim.2024.0034
Aug 2024  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
38th treatment shown to reduce risk in May 2022, now with p = 0.000054 from 18 studies, recognized in 31 countries. Efficacy is variant dependent.
Lower risk for mortality, hospitalization, and cases.
No treatment is 100% effective. Protocols combine treatments.
5,300+ studies for 116 treatments. c19early.org
Review of the successful treatment of COVID-19 using existing medications including HCQ, AZ, ivermectin, famotidine, monoclonal antibodies, and others. Authors note that the typical treatment of severe viral infections with multiple therapeutic agents has generally not been done in COVID-19 clinical trials, that different mechanisms of action from multiple treatments can minimize the emergence of drug-resistant SARS-CoV-2 strains, and that early treatment disrupts viral replication, avoids progression to cytokine storm, and is critical to avoid long-term complications.
Efficacy is variant dependent. In Vitro research suggests a lack of efficacy for omicron BA.2.75.2, BA.4.6, BQ.1.11, BA.5, BA.2.75, XBB2,3, XBB.1.53, ХВВ.1.9.13, XBB.1.9.3, XBB.1.5.24, XBB.1.16, XBB.2.9, BQ.1.1.45, CL.1, and CH.1.14.
Reviews covering tixagevimab/cilgavimab for COVID-19 include5-8.
Review covers ivermectin, HCQ, famotidine, bebtelovimab, tixagevimab/cilgavimab, and sotrovimab.
Enyeji et al., 5 Aug 2024, peer-reviewed, 3 authors.
This PaperTixagev../c..All
DOI record: { "DOI": "10.1089/vim.2024.0034", "ISSN": [ "0882-8245", "1557-8976" ], "URL": "http://dx.doi.org/10.1089/vim.2024.0034", "alternative-id": [ "10.1089/vim.2024.0034" ], "author": [ { "ORCID": "http://orcid.org/0000-0002-2653-8605", "affiliation": [ { "name": "Division of Community Medicine, Mercer University School of Medicine, Columbus, Georgia, 31901, USA." } ], "authenticated-orcid": false, "family": "Enyeji", "given": "Abraham M.", "sequence": "first" }, { "affiliation": [ { "name": "Georgetown University, Data Science and Analytics Washington, DC 20057, USA." } ], "family": "Arora", "given": "Amit", "sequence": "additional" }, { "affiliation": [ { "name": "Germantown Medical Health Center, Germantown, Maryland, 20876 USA." } ], "family": "Mangat", "given": "Harpal S.", "sequence": "additional" } ], "container-title": "Viral Immunology", "container-title-short": "Viral Immunology", "content-domain": { "crossmark-restriction": false, "domain": [] }, "created": { "date-parts": [ [ 2024, 8, 3 ] ], "date-time": "2024-08-03T11:03:52Z", "timestamp": 1722683032000 }, "deposited": { "date-parts": [ [ 2024, 8, 5 ] ], "date-time": "2024-08-05T14:00:56Z", "timestamp": 1722866456000 }, "indexed": { "date-parts": [ [ 2024, 8, 6 ] ], "date-time": "2024-08-06T00:25:30Z", "timestamp": 1722903930363 }, "is-referenced-by-count": 0, "issued": { "date-parts": [ [ 2024, 8, 5 ] ] }, "language": "en", "license": [ { "URL": "https://www.liebertpub.com/nv/resources-tools/text-and-data-mining-policy/121/", "content-version": "tdm", "delay-in-days": 0, "start": { "date-parts": [ [ 2024, 8, 5 ] ], "date-time": "2024-08-05T00:00:00Z", "timestamp": 1722816000000 } } ], "link": [ { "URL": "https://www.liebertpub.com/doi/full-xml/10.1089/vim.2024.0034", "content-type": "application/xml", "content-version": "vor", "intended-application": "text-mining" }, { "URL": "https://www.liebertpub.com/doi/pdf/10.1089/vim.2024.0034", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking" } ], "member": "278", "original-title": [], "prefix": "10.1089", "published": { "date-parts": [ [ 2024, 8, 5 ] ] }, "published-online": { "date-parts": [ [ 2024, 8, 5 ] ] }, "publisher": "Mary Ann Liebert Inc", "reference": [ { "DOI": "10.1007/978-3-030-88863-3_14", "doi-asserted-by": "publisher", "key": "B1" }, { "DOI": "10.13016/i1wo-er4h", "doi-asserted-by": "publisher", "key": "B2" }, { "DOI": "10.1093/cid/ciac663", "doi-asserted-by": "publisher", "key": "B4" }, { "DOI": "10.1016/j.rce.2020.05.006", "doi-asserted-by": "publisher", "key": "B5" }, { "DOI": "10.1001/jamaoto.2020.1922", "doi-asserted-by": "publisher", "key": "B6" }, { "DOI": "10.7554/eLife.59177", "doi-asserted-by": "publisher", "key": "B7" }, { "DOI": "10.3390/ijms22115438", "doi-asserted-by": "publisher", "key": "B8" }, { "author": "Mangat HS", "first-page": "1088", "issue": "2", "journal-title": "Health Sci J", "key": "B9", "volume": "17", "year": "2023" }, { "DOI": "10.29121/granthaalayah.v8.i7.2020.678", "doi-asserted-by": "publisher", "key": "B10" }, { "DOI": "10.1016/j.jinf.2020.07.005", "doi-asserted-by": "publisher", "key": "B11" }, { "DOI": "10.1111/head.14006", "doi-asserted-by": "publisher", "key": "B12" }, { "DOI": "10.1016/j.envres.2020.109754", "doi-asserted-by": "publisher", "key": "B13" }, { "DOI": "10.34172/jrip.2020.19", "doi-asserted-by": "publisher", "key": "B14" }, { "DOI": "10.1126/SCIADV.ABD4049", "doi-asserted-by": "publisher", "key": "B15" } ], "reference-count": 14, "references-count": 14, "relation": {}, "resource": { "primary": { "URL": "https://www.liebertpub.com/doi/10.1089/vim.2024.0034" } }, "score": 1, "short-title": [], "source": "Crossref", "subject": [], "subtitle": [], "title": "Effective Treatment of COVID-19 Infection with Repurposed Drugs: Case Reports", "type": "journal-article" }
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit